Zenas BioPharma (NASDAQ:ZBIO) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of Zenas BioPharma (NASDAQ:ZBIO) from a hold rating to a strong sell rating in a research note released on Tuesday morning,Zacks.com reports.

Other analysts have also issued research reports about the company. Citigroup decreased their price objective on Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday. Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Guggenheim increased their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Zenas BioPharma in a report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma has an average rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $23.37 on Tuesday. The firm’s 50-day moving average is $23.05 and its 200-day moving average is $27.12. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -2.99 and a beta of -1.94. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.66 and a current ratio of 5.61. Zenas BioPharma has a 52-week low of $6.11 and a 52-week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Buying and Selling

In related news, CEO Leon O. Moulder, Jr. acquired 57,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was purchased at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the purchase, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at $7,599,863.80. The trade was a 15.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hongbo Lu acquired 25,985 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were bought at an average cost of $22.50 per share, with a total value of $584,662.50. Following the completion of the acquisition, the director owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. This trade represents a 8.07% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 202,845 shares of company stock worth $3,747,185 in the last 90 days. 16.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds have recently made changes to their positions in the company. Polar Capital Holdings Plc bought a new position in Zenas BioPharma during the 4th quarter valued at about $38,402,000. Federated Hermes Inc. raised its stake in shares of Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after acquiring an additional 853,740 shares during the last quarter. EcoR1 Capital LLC bought a new position in shares of Zenas BioPharma in the fourth quarter valued at approximately $28,667,000. NEA Management Company LLC raised its stake in shares of Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after acquiring an additional 789,500 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new position in shares of Zenas BioPharma in the 4th quarter worth approximately $11,691,000.

Zenas BioPharma News Roundup

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $44 price target on Zenas BioPharma — a bullish anchor that can support demand even as the firm revised estimates. HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO)
• Neutral Sentiment: Technical/background context: the stock is trading near its 50-day moving average with below-average volume and remains well off its 52‑week high — trading dynamics that can amplify the impact of analyst notes. Zenas BioPharma (ZBIO) Market Data
• Negative Sentiment: Zacks Research downgraded Zenas from “Hold” to “Strong Sell,” a clear negative signal that can pressure sentiment and attract short‑term selling. Zacks.com
• Negative Sentiment: HC Wainwright significantly lowered EPS forecasts across Q1–Q4 2026 and multiple outyears (FY2026–FY2030), cutting FY2026 and subsequent year estimates materially — this weakens near‑term fundamentals despite the Buy rating. Zenas BioPharma analyst estimate updates
• Negative Sentiment: Citigroup lowered its price target to $41, another downward revision to modeled upside that could cap gains if other analysts follow suit. Zenas BioPharma (NASDAQ:ZBIO) Price Target Cut to $41.00 by Analysts at Citigroup

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.